Document is current
Any future updates will be listed below
-
Authors
Ewing, Ailith https://orcid.org/0000-0002-2272-1277
Meynert, Alison
Silk, Ryan https://orcid.org/0000-0001-6421-1294
Aitken, Stuart https://orcid.org/0000-0003-4867-4568
Bendixsen, Devin P. https://orcid.org/0000-0003-0831-7646
Churchman, Michael
Brown, Stuart L.
Hamdan, Alhafidz https://orcid.org/0000-0002-0794-5504
Mattocks, Joanne
Grimes, Graeme R.
Ballinger, Tracy
Hollis, Robert L. https://orcid.org/0000-0002-1390-3298
Simon Herrington, C. https://orcid.org/0000-0001-9177-8165
Thomson, John P.
Sherwood, Kitty https://orcid.org/0009-0007-4055-607X
Parry, Thomas
Esiri-Bloom, Edward https://orcid.org/0000-0003-0685-2629
Bartos, Clare
Croy, Ian
Ferguson, Michelle
Lennie, Mairi
McGoldrick, Trevor
McPhail, Neil
Siddiqui, Nadeem
Glasspool, Rosalind https://orcid.org/0000-0002-5000-1680
Mackean, Melanie
Nussey, Fiona
McDade, Brian
Ennis, Darren https://orcid.org/0000-0001-5260-3506
,
McMahon, Lynn
Matakidou, Athena
Dougherty, Brian
March, Ruth
Carl Barrett, J.
McNeish, Iain A. https://orcid.org/0000-0002-9387-7586
Biankin, Andrew V. https://orcid.org/0000-0002-0362-5597
Roxburgh, Patricia https://orcid.org/0000-0001-9869-591X
Gourley, Charlie https://orcid.org/0000-0002-2377-7221
Semple, Colin A. https://orcid.org/0000-0003-1765-4118
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 30 May 2025
First Online: 1 July 2025
Competing interests
: C.G. receives research funding from AstraZeneca, MSD, Novartis, GSK, BerGen Bio, Medannex, Roche, Verastem, Artios and personal fees from AstraZeneca, MSD, GSK, Clovis, Verastem, Takeda, Eisai, Cor2Ed, Peer Voice. PR received honoraria from AstraZeneca. RH received consultancy fees from GSK and DeciBio. BD and RM are employees and stockholders of AstraZeneca. IMcN is or was previously on the advisory boards for Clovis Oncology, Tesaro, AstraZeneca, Carrick Therapeutics, Roche and ScanCell. IMcN also benefits from institutional funding from AstraZeneca. R.G. is or has been on the advisory boards of AstraZeneca, GSK, Tesaro and Clovis; has received speaker fees and funding to attend medical conferences from GSK and Tesaro and is a UK co-ordinating investigator or site principal investigator for studies sponsored by AstraZeneca, GSK, Pfizer and Clovis. The remaining authors declare no competing interests.
